Image: by Roland1952, CC BY-SA 3.0Nucleic acid drugs are mainly divided into
two major categories: small nucleic acid drugs and mRNA.
Small nucleic acid drugs, also known as oligonucleotide drugs, include antisense
nucleotides (ASO), small
interfering RNA (siRNA), microRNA, nucleic acid aptamers, and
others. mRNA products can be further categorized into mRNA vaccines and
mRNA drugs.
By Carrie Taylor, Director of Business
Development of BOCSCI
Characteristics of Nucleic Acid Drugs

Nucleic acid drugs offer distinct
advantages. Traditional small molecule and antibody drugs primarily function by
binding to target proteins, but their development is often constrained by the
druggability of these target proteins. In contrast, nucleic acid drugs modulate
genes associated with protein expression, enabling them to regulate both
intracellular and extracellular proteins, as well as membrane-bound proteins.
Moreover, most nucleic acid drugs operate on the principle of base-pairing
complementarity, making sequence design relatively straightforward once the target
gene’s base sequence is known.
However, limitations such as instability,
immunogenicity, low cellular uptake efficiency, and difficulties in escaping
endocytic pathways have restricted the development of nucleic acid drugs. To
address the challenges associated with the molecules themselves, the
development of delivery carrier systems that facilitate the uptake of nucleic
acids into target cells has become crucial. These delivery carriers need to
overcome barriers both extracellularly and intracellularly, withstand nucleases
in the bloodstream, enhance and assist in cellular uptake of nucleic acid
drugs, and promote intracellular escape of the nucleic acid drugs once inside
the cell.
Nucleic Acid Drug Delivery
System
In the early stages of research, viruses
were commonly used as carriers for delivering nucleic acids. Virus carriers
utilized in clinical trials included adenovirus (Ad), adeno-associated virus
(AAV), lentivirus (LV), herpes simplex virus (HSV), and others. However, some
virus carriers exhibited undesirable characteristics, such as potential
carcinogenicity and high immunogenicity, which led to serious clinical adverse
events and hindered the research on their clinical applications. With the
development of materials and preparation techniques, non-viral carriers that
are cost-effective, easily synthesized, purified, and possess high transfection
efficiency with low immunogenicity have emerged as the “optimal candidates” for
delivering nucleic acid drugs.
1. GalNac Modification
GalNac (N-acetylgalactosamine) conjugate
modification is the most commonly used nucleic acid drug delivery system today.
GalNac is a lactose analog covalently attached to the 3′ end of nucleic acids
in a trivalent form.
Following subcutaneous injection of GalNac-siRNA
conjugates, they can rapidly enter the liver through the circulatory
system. Subsequently, they are rapidly internalized by liver cells through
ASPGR receptor-mediated uptake, accumulate in lysosomes, and are slowly
released, continuously loading onto the RNA
Currently, drugs modified with GalNAc
primarily include GalNAc-antisense oligonucleotides (ASO) and GalNAc-siRNA.
Since effective ASOs for therapy have already undergone extensive
modifications, a delivery carrier is not necessary. siRNAs, on the other hand,
are prone to degradation on their own, so carrier delivery technologies are
often employed.
2. Nanoparticles
(1) Lipid
Nanoparticle
Lipid Nanoparticle (LNP), is one of the important
technologies in lipid carrier drug delivery system. The main components are
categorized into the following four types:
- Ionic lipids that can be ionized are the
most crucial excipients and serve as determinants of delivery and transfection
efficiency. Due to their relatively easy uptake by antigen-presenting cells,
they are commonly used in vaccines.
-
Neutral helper lipids, typically saturated
lipids, can increase the phase transition temperature of cationic liposomes,
support the formation of a lamellar lipid bilayer structure, and stabilize its
structural arrangement.
-
Cholesterol, possessing strong membrane
fusion capabilities, facilitates intracellular uptake and cytoplasmic entry of
mRNA.
-
PEGylated lipids, located on the surface of
lipid nanoparticles, enhance their hydrophilicity, prevent rapid clearance by
the immune system, prevent particle aggregation, and increase stability.
(2) Polymer
Nanoparticles
Cationic polymers have become another major
type of non-viral gene delivery vector due to their ease of synthesis and
flexibility. Polymers can bind with nucleic acids to form polycomplexes at
physiological pH, facilitating gene delivery. Typically, polymer nanoparticles
contain positively charged units that promote electrostatic binding with
nucleic acids. Additionally, covalent linkage between nucleic acids and
polymers can be achieved using degradable linkers. Common polymer materials
include polyethylenimine (PEI) and chitosan (CS).
Another class of polymers used for RNA
delivery is dendrimers. These large molecules have a core molecule at their
center and are synthesized through repeated growth reactions, resulting in
highly branched polymers. Dendrimers carrying cationic groups can form
complexes with RNA. Research has shown that they can deliver RNA to the central
nervous system and siRNA to liver endothelial cells. Modifying the structure of
dendrimers can protect nucleotides from enzymatic degradation.
siG12D-LODER is a biodegradable polymer
matrix containing siRNA targeting KRASG12D. Currently, Novartis is conducting
Phase II clinical trials for siG12D-LODER to assess its effectiveness in
combination with chemotherapy drugs like gemcitabine and paclitaxel in treating
locally advanced pancreatic cancer patients.
(3) Inorganic Nanoparticles
Gold nanoparticles have unique optical
properties, ease of synthesis and surface functionalization, and can be
selectively and synergistically modified with nucleic acids through covalent or
non-covalent affixation. Nucleic acid chains are covalently attached to the
gold nanoparticle core (typically 13-15 nm) via thiol groups. This strategy can
be used for DNA and siRNA, which can be directly attached to gold cores or
polymer-modified gold cores.
Spherical nucleic acids (SNA) are composed
of nucleic acids arranged on the surface of small spherical gold nanoparticles.
The platform drug, NU-0129, is currently being studied in a clinical phase 1
study in recurrent glioma. Once NU-0129 crosses the blood-brain barrier
and enters the tumor, the nucleic acid component is able to target a gene
called Bcl2L12. The researchers believe that targeting the Bcl2L12 gene with
NU-0129 will help stop the growth of gliomas.
Silica nanoparticles (100-250 nm in
diameter), are used for nucleic acid delivery due to their good
biocompatibility and tunability. Typically, nucleic acid molecules are loaded
into silica nanoparticles through weak non-covalent interactions. Small pore
(2.5-5 nm) silica nanoparticles are suitable for delivery of small siRNA.
Iron oxide nanoparticles (consisting of
Fe3O4 or Fe2O3) have superparamagnetic properties of a certain size and
show success as delivery carriers and magnetothermal based therapies. Cationic
iron oxide nanoparticles and anionic nucleic acid drugs, bind to each other by
electrostatic forces. 50-100 nm lipid-coated iron oxide nanoparticles show
optimal siRNA delivery activity.
3. New Delivery Systems
(1) Exosomes
Extracellular vesicles, derived from
endosomes and released into the extracellular space through multivesicular body
fusion with the cell membrane, are membrane-bound vesicular structures with
diameters ranging between 50 and 150 nm. These extracellular vesicles contain
various biological macromolecules, including proteins, nucleic acids, and
lipids. Extracellular vesicles can transfer a variety of biological
macromolecules between cells, making them a drug delivery method with
significant inherent advantages.
- Firstly, extracellular vesicles are
“naturally tamed” nanocarriers that inherently contain multiple active
components, allowing them to carry a wide range of drug types, including small
molecules, nucleic acids, and recombinant proteins.
-
Secondly, as endogenous nanoparticles,
extracellular vesicles have low immunogenicity, resulting in high safety.
-
Thirdly, extracellular vesicles can circulate
through all the body’s cavities, exhibiting good tissue selectivity.
-
Finally, complex engineering modifications
can be applied to extracellular vesicles through genetic or chemical
approaches, allowing precise control over their composition and biological
functions, thus better serving our therapeutic purposes.
(2) Peptides
The current technologies used in nucleic
acid drug delivery that are on the market today do not effectively address the
issue of tissue-specific targeting. Peptides offer solutions to many problems
that other delivery systems cannot resolve. Chemical modifications of
non-natural amino acids have greatly improved the half-life of peptide drugs in
the body. The development of cyclization techniques has increased the rigidity
of peptide structures, significantly enhancing their affinity for target
proteins. Peptide-drug conjugates (PDCs) exhibit strong tumor penetration, low
immunogenicity, and renal metabolism, among other characteristics.

Currently, companies like Ionis, Alnylam,
Entrada Therapeutics, and others are actively establishing platforms for peptide-nucleic
acid conjugate drugs. The future looks promising for
peptide-nucleic acid conjugates.
(3) Others
Renowned scientist Zhang Feng’s company,
Aera Therapeutics, has introduced a novel delivery platform called Protein
Nanoparticles (PNP), which utilizes endogenous human proteins to address the
limitations of current delivery technologies.
Altamira Therapeutics, a biotechnology
company focused on RNA therapy, has announced the development of an innovative
peptide-based SemaPhoreTM nanoparticle technology platform. This delivery
platform is designed for safe and effective systemic or local administration of
oligonucleotides such as siRNA and mRNA to target cells. Currently, the company
has established two preclinical siRNA projects on this platform for the
treatment of KRAS-driven cancers and rheumatoid arthritis.
Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)